Abstract
Beauveriolide F, of >98 % purity (HPLC); CAS 75947-00-1; the cyclopeptide (3R,6S,9S)-6,9-dibenzyl-3-[(2R)-butan-2-yl]-13-hexan-2-yl-1-oxa-4,7,10-triazacyclotridecane-2,5,8,11-tetrone, where: 3OH4MeC8a stands for the 3(R)-hydroxy-4(S)-methyloctanoic acid Residue, Phe, L (S)-phenylalanine, Leu, D (R)-leucine. The substance was isolated by a newly developed procedure from the production strain of the fungus Beauveria (monosporic isolate).
It is produced at a purity > 98%. The physicochemical properties of the product have been described in detail in the accompanying safety data sheet (SDD) and the functional sample certificate.
The substance is one of major bioactive metabolites of several species of entomopathogenic fungi of the genus Beauveria, Isaria or Paecilomyces. BVD-F is predicted to inhibit the enzyme acyl CoA: cholesterol acyltransferase (ACAT1 and ACAT2) and is predicted to be included in a new class of substances that reduce the accumulation of β-amyloid peptides in the brain, one of the major manifestations of Alzheimer's disease and to slow down some neurodegenerative processes during aging.